Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Recommendation of “Moderate Buy” from Analysts

by · The Markets Daily

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) have received a consensus rating of “Moderate Buy” from the nine brokerages that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and eight have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $64.4286.

DNTH has been the subject of a number of recent analyst reports. HC Wainwright increased their price target on shares of Dianthus Therapeutics from $40.00 to $47.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Truist Financial upped their target price on shares of Dianthus Therapeutics from $56.00 to $63.00 and gave the company a “buy” rating in a report on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Wednesday, October 8th. Finally, Wedbush reissued an “outperform” rating and set a $46.00 price target on shares of Dianthus Therapeutics in a research report on Monday, December 22nd.

Read Our Latest Stock Analysis on DNTH

Dianthus Therapeutics Stock Up 0.2%

DNTH stock opened at $38.19 on Tuesday. The company has a market cap of $1.64 billion, a price-to-earnings ratio of -10.97 and a beta of 1.55. Dianthus Therapeutics has a twelve month low of $13.36 and a twelve month high of $45.46. The business has a 50 day moving average price of $40.69 and a two-hundred day moving average price of $32.08.

Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.11). Dianthus Therapeutics had a negative return on equity of 33.02% and a negative net margin of 4,106.04%.The company had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.58 million. On average, equities research analysts anticipate that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

Insider Buying and Selling

In other Dianthus Therapeutics news, EVP Simrat Randhawa sold 109,031 shares of Dianthus Therapeutics stock in a transaction on Friday, November 14th. The shares were sold at an average price of $38.14, for a total transaction of $4,158,442.34. Following the completion of the transaction, the executive vice president directly owned 4,000 shares of the company’s stock, valued at $152,560. The trade was a 96.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Ryan Savitz sold 20,000 shares of the company’s stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $45.18, for a total transaction of $903,600.00. The SEC filing for this sale provides additional information. Insiders have sold a total of 216,538 shares of company stock worth $8,283,175 over the last three months. 8.15% of the stock is owned by insiders.

Institutional Trading of Dianthus Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of DNTH. Raymond James Financial Inc. acquired a new position in Dianthus Therapeutics in the 2nd quarter valued at about $27,000. Parkside Financial Bank & Trust boosted its holdings in shares of Dianthus Therapeutics by 131.7% during the third quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock worth $37,000 after acquiring an additional 540 shares during the period. Russell Investments Group Ltd. acquired a new position in shares of Dianthus Therapeutics in the third quarter valued at approximately $64,000. Tower Research Capital LLC TRC grew its position in shares of Dianthus Therapeutics by 330.7% in the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock valued at $80,000 after purchasing an additional 3,317 shares during the last quarter. Finally, AlphaQuest LLC bought a new position in shares of Dianthus Therapeutics during the second quarter worth approximately $94,000. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

(Get Free Report)

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.

Read More